Duloxetine Zentiva

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
16-08-2022
Tabia za bidhaa Tabia za bidhaa (SPC)
16-08-2022

Viambatanisho vya kazi:

duloxetine

Inapatikana kutoka:

Zentiva, k.s.

ATC kanuni:

N06AX21

INN (Jina la Kimataifa):

duloxetine

Kundi la matibabu:

Other antidepressants

Eneo la matibabu:

Neuralgia; Depressive Disorder, Major; Anxiety Disorders; Diabetes Mellitus

Matibabu dalili:

Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder. Duloxetine Zentiva is indicated in adults.,

Bidhaa muhtasari:

Revision: 11

Idhini hali ya:

Authorised

Idhini ya tarehe:

2015-08-20

Taarifa za kipeperushi

                                33
B. PACKAGE LEAFLET
34
PACKAGE LEAFLET: INFORMATION FOR THE USER
DULOXETINE ZENTIVA 30 MG GASTRO-RESISTANT HARD CAPSULES
DULOXETINE ZENTIVA 60 MG GASTRO-RESISTANT HARD CAPSULES
duloxetine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor or pharmacist.
−
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
−
If you get any of the side effects, talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Duloxetine Zentiva is and what it is used for
2.
What you need to know before you take Duloxetine Zentiva
3.
How to take Duloxetine Zentiva
4.
Possible side effects
5.
How to store Duloxetine Zentiva
6.
Contents of the pack and other information
1.
WHAT DULOXETINE ZENTIVA IS AND WHAT IT IS USED FOR
Duloxetine Zentiva contains the active substance duloxetine.
Duloxetine Zentiva increases the levels
of serotonin and noradrenaline in the nervous system.
Duloxetine Zentiva is used in adults to treat:
•
depression;
•
generalised anxiety disorder (chronic feeling of anxiety or
nervousness);
•
diabetic neuropathic pain (often described as burning, stabbing,
stinging, shooting or aching or
like an electric shock. There may be loss of feeling in the affected
area, or sensations such as
touch, heat, cold or pressure may cause pain).
Duloxetine Zentiva starts to work in most people with depression or
anxiety within two weeks of
starting treatment, but it may take 2-4 weeks before you feel better.
Tell your doctor if you do not start
to feel better after this time. Your doctor may continue to give you
Duloxetine Zentiva when you are
feeling better to prevent your depression or anxiety from returning.
In people with diabetic neuropathic pain it can take 
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Duloxetine Zentiva 30 mg gastro-resistant hard capsules
Duloxetine Zentiva 60 mg gastro-resistant hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Duloxetine Zentiva 30 mg gastro-resistant hard capsules
Each capsule contains duloxetine hydrochloride equivalent to 30 mg
duloxetine.
Excipient(s) with known effect
Each capsule contains 42.26 – 46.57 mg of sucrose.
Duloxetine Zentiva 60 mg gastro-resistant hard capsules
Each capsule contains duloxetine hydrochloride equivalent to 60 mg
duloxetine.
Excipient(s) with known effect
Each capsule contains 84.51 - 93.14 mg of sucrose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant hard capsule
Duloxetine Zentiva 30 mg gastro-resistant hard capsules
Hard opaque gelatin capsules of length approx. 15.9 mm with white
opaque body and light-blue
opaque cap which contain off-white to light-brown-yellow spherical
pellets.
Duloxetine Zentiva 60 mg gastro-resistant hard capsules
Hard opaque gelatin capsules of length approx. 19.4 mm with ivory
opaque body and light-blue
opaque cap which contain off-white to light-brown-yellow spherical
pellets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of major depressive disorder.
Treatment of diabetic peripheral neuropathic pain.
Treatment of generalised anxiety disorder.
Duloxetine Zentiva is indicated in adults.
For further information see section 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Major depressive disorder _
The starting and recommended maintenance dose is 60 mg once daily with
or without food. Dosages
above 60 mg once daily, up to a maximum dose of 120 mg per day have
been evaluated from a safety
perspective in clinical trials. However, there is no clinical evidence
suggesting that patients not
responding to the initial recommended dose may benefit from dose
up-titrations.
Therapeutic response is usually seen after 2-4 weeks of treatment.
After consolidation of the anti
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kibulgaria 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kihispania 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kicheki 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kidenmaki 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kijerumani 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kiestonia 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kigiriki 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kifaransa 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kiitaliano 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kilatvia 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kilithuania 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kihungari 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kimalta 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kiholanzi 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kipolandi 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kireno 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kiromania 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kislovakia 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kislovenia 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kifinlandi 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kiswidi 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 27-08-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kinorwe 16-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 16-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 16-08-2022
Tabia za bidhaa Tabia za bidhaa Kroeshia 16-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 27-08-2015

Tafuta arifu zinazohusiana na bidhaa hii